IGH (Immunoglobulin Heavy Locus)

Specific proteins and phosphopeptides identified here, upon further validation, may serve as biomarkers for early intervention in UM‑CLL. More broadly, our study demonstrates the value of integrated proteomic and phosphoproteomic profiling which may lead to refining risk stratification and advancing understanding of the complex biology underlying CLL progression.

Despite molecular features associated with a favorable prognosis, the severity of his presentation prompted the initiation of therapy after the exclusion of alternative etiologies. This case highlights the diagnostic and therapeutic uncertainty created by atypical symptomatic presentation of CLL and the prognostic ambiguity of IGHV3-21 CLL requiring cautious interpretation.

P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

Furthermore, Stag2 is also highly expressed in the GC B cells within different cancers, corresponding to the high level of CSR. Our findings uncover the unrecognized specific roles of Stag2 in regulating CSR.

While polygenic risk scores (PRS) provide insight into inherited susceptibility, they are not yet clinically actionable for risk stratification or screening in MM and currently remain research tools. This framework provides a clinically oriented basis for applying genomic biomarkers to risk stratification, treatment selection, and longitudinal monitoring.

In an efficacy cohort of 3832 previously untreated patients from GCLLSG trials, IGH::BCL3 was associated with shorter progression-free survival (PFS) and overall survival (OS) in 28 patients when treated with chemoimmunotherapy, but not in those receiving venetoclax. Our findings highlight the genetic and epigenetic homogeneity of IGH::BCL3-translocated CLL samples and their differences from other types of CLL, suggesting IGH::BCL3 leukemic B-cell neoplasms to be a biological distinct type within the spectrum of mature lymphatic leukemia/CLL.

We further discuss how disruption of condensate dynamics-either through impaired assembly or pathological stabilization-can compromise repair fidelity, contributing to immunodeficiency and B cell lymphomagenesis. By positioning CSR as a paradigm for studying higher-order nuclear organization during programmed genome rearrangements, this review highlights how condensate-based regulation may contribute to immune diversification and genome stability.

The patient achieved complete remission after six cycles of obinutuzumab, cyclophosphamide, vincristine, and prednisone. This case illustrates a rare presentation of nontranslocation follicular lymphoma mimicking infectious mononucleosis and emphasizes the importance of reconsidering hematologic malignancy in patients with persistent mucocutaneous inflammation and incongruent laboratory findings.

P1/2, N=25, Not yet recruiting, AstraZeneca AB

P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Feb 2027

Similarly, METRNL, located at the telomere of chromosome 17q25, was identified as a translocation partner gene in four cases. Our findings expand the spectrum of the oncogenic translocation partners targeting IGH in CLL.

This study is the first to report real-world evidence on treatment choice in first-line CLL and highlight two distinct groups of patients.